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ING3 promotes prostate cancer growth by
activating the androgen receptor
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Abstract
Background: The androgen receptor (AR) is a major driver of prostate cancer, and increased AR levels and co-activators
of the receptor promote the development of prostate cancer. INhibitor of Growth (ING) proteins target lysine
acetyltransferase or lysine deacetylase complexes to the histone H3K4Me3 mark of active transcription, to affect chromatin
structure and gene expression. ING3 is a stoichiometric member of the TIP60 lysine acetyltransferase complex implicated
in prostate cancer development.
Methods: Biopsies of 265 patients with prostate cancer were stained for ING3, pan-cytokeratin, and DNA. LNCaP and C4-2
androgen-responsive cells were used for in vitro assays including immunoprecipitation, western blotting, Luciferase
reporter assay and quantitative polymerase chain reaction. Cell viability and migration assays were performed in prostate
cancer cell lines using scrambled siRNA or siRNA targeting ING3.
Results: We find that ING3 levels and AR activity positively correlate in prostate cancer. ING3 potentiates androgen
effects, increasing expression of androgen-regulated genes and androgen response element-driven reporters to
promote growth and anchorage-independent growth. Conversely, ING3 knockdown inhibits prostate cancer cell
growth and invasion. ING3 activates the AR by serving as a scaffold to increase interaction between TIP60 and the AR
in the cytoplasm, enhancing receptor acetylation and translocation to the nucleus. Activation is independent of ING3's
ability to target the TIP60 complex to H3K4Me3, identifying a previously unknown chromatin-independent cytoplasmic
activity for ING3. In agreement with in vitro observations, analysis of The Cancer Genome Atlas (TCGA) data (n = 498)
and a prostate cancer tissue microarray (n = 256) show that ING3 levels are higher in aggressive prostate cancers, with
high levels of ING3 predicting shorter patient survival in a low AR subgroup. Including ING3 levels with currently used
indicators such as the Gleason score provides more accurate prognosis in primary prostate cancer.
Conclusions: In contrast to the majority of previous reports suggesting tumor suppressive functions in other cancers,
our observations identify a clear oncogenic role for ING3, which acts as a co-activator of AR in prostate cancer. Data
from TCGA and our previous and current tissue microarrays suggest that ING3 levels correlate with AR levels and that
in patients with low levels of the receptor, ING3 level could serve as a useful prognostic biomarker.
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Background
Prostate cancer (PC) is the most frequently occurring
male malignancy worldwide. In 2015, more than 220,000
new cases and 27,000 PC-related deaths were reported in
the USA [1]. Treatment options include surgery, radiation
therapy, and androgen deprivation therapy (ADT).
Although most patients initially respond to ADT, they
frequently develop recurrent castrate-resistant PC (CRPC)
[2] for which management options are limited to aggres-
sive chemotherapy and palliative care.
The androgen receptor (AR) is the central transcrip-
tion factor in PC biology and pathogenesis. After bind-
ing to androgens, the AR translocates to the nucleus,
forms homodimers, and binds androgen response ele-
ments (AREs) in the promoters of target genes, altering
their expression. In primary PC, the inhibition of the AR
pathway by anti-androgens leads to dramatic tumor
regression. In CRPC, however, tumors acquire resistance
to ADT but remain dependent on AR through molecular
alterations including AR amplification, mutations, splice
variants, as well as overexpression of AR co-activators
[3–6]. Co-activators include chaperone proteins, mem-
bers of the p160 family, DNA repair proteins, ubiquitin
ligases, histone demethylases, and acetyltransferases,
inter alia [7]. Lysine (K) acetyltransferases (KATs) such
as p300 and TIP60 have been reported to acetylate and
activate the AR in metastatic PC [8–12].
We identified the first member of the INhibitor of
Growth (ING) family of epigenetic regulators using PCR-
mediated subtractive hybridization between normal and
cancerous breast epithelial cells [13], and ING2–5 were
subsequently identified by sequence homology [14–16].
ING proteins are stoichiometric members of histone/lysine
acetyltransferase (KAT; ING3–5) or histone/lysine deacety-
lase (KDAC; ING1, ING2) complexes [17]. They specifically
recognize H3K4Me3 and recruit KAT or KDAC complexes
to alter the chromatin structure [18]. We noted that Yng2,
the budding yeast homolog of ING3, is a member of the
NuA4 KAT complex, and that deletion of Yng2 caused se-
vere cell cycle and growth defects [19]. Affinity purification
followed by mass spectrometry showed that human ING3
is an essential and stoichiometric member of the TIP60
KATcomplex that is analogous to NuA4, and its role in this
complex is conserved from yeast to mammals [20].
Early studies reported that, similar to ING1, ING3
functions as a type II tumor suppressor to regulate apop-
tosis and is downregulated in cancers such as melanoma
and head and neck carcinoma [15, 21, 22]. However, more
recent examination of ING3 function in regulating cardiac
hypertrophy indicated a positive growth effect through
mTOR [23], and using new, more reliable immunological
reagents than were previously available, we found that
ING3 is highly expressed in proliferating human tissues
such as skin, small intestine, and bone marrow [24].
In a recent screening study, it was noted that high ING3
levels correlate with worse prognosis in patients with
erythroblast transformation-specific-related gene (ERG)
negative PC, and that a ten-gene signature that correlates
with patient survival in these cancers included ING3 [25,
26]. However, the mechanism by which ING3 contributes to
ERG-negative PC and its role in PC biology in general were
not characterized. Here, we show that ING3 is an AR co-
activator, which promotes TIP60-mediated AR acetylation
and nuclear translocation, leading to PC cell proliferation
and migration. In addition, we provide evidence that ING3
levels correlate with AR levels in PC patient samples, and
show that higher ING3 levels serve as a biomarker predict-
ing poorer prognosis in patients with low AR expression.
Methods
Cell culture, plasmids, and transfection
LNCaP, VCaP, PC3, DU145, and HEK293T cell lines were
purchased from American Type Culture Collection
(ATCC), and C4-2 cells were a gift from Dr. Martin Gleave.
All lines were periodically checked for mycoplasma by
PCR. LNCaP, C4-2, and PC3 were grown in Roswell Park
Memorial Institute (RPMI) medium supplemented with
10% fetal bovine serum (FBS). DU145, VCaP, and
HEK293T cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% FBS. For andro-
gen deprivation, cells were incubated with media supple-
mented with 5% charcoal stripped FBS (CSS) (Invitrogen)
for 48 h. Mibolerone (MB) (Toronto Research Chemicals)
was used as an androgen analog at concentrations of 1–10
nM. The pCMV-3myc-AR plasmid was a gift from Dr.
Marja Nevalainen. The pCIN4-FLAG-HA-TIP60 was a gift
from Dr. Wei Gu. HEK293T cells were transfected using
TransIT 293 reagent (Mirus), and PC cells were transfected
using Lipofectamine LTX (Invitrogen). Knockdown of
ING3 by small interfering ING3 (siING3) was done as pre-
viously described [24].
Lentiviral short hairpin RNA (shRNA) generation and
infection
Three shRNA sequences against ING3 (shING3) derived
from the RNA interference (RNAi) codex and a scrambled
shRNA (shCtrl) with similar GC content were cloned in
pINDUCER10, a doxycycline (Dox)-inducible lentiviral
vector [27]. C4-2 cells were infected with concentrated
inducible lentivirus encoding either shCtrl or shING3. After
the addition of Dox, cells were sorted keying on red fluores-
cent protein (RFP) expression (Additional file 1: Figure S1).
Immunoprecipitation (IP)
For IP, 1 × 107 cells were lysed at 4 °C using lysis buffer
(50 mM Tris-HCL, 150 mM NaCl, 1 mM ethylenediamine-
tetraacetic acid (EDTA), 1% Triton X-100) supplemented
with protease inhibitors (cOmplete, Roche). Antibodies
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including anti-HA (Roche), anti-Myc (Sigma), anti-acetyl
lysine (Santa Cruz Biotechnology), anti-ING3 (Kerafast
[24]), anti-AR (N-20, Santa Cruz Biotechnology), or anti-
TIP60 (C-7, Santa Cruz Biotechnology) were crosslinked to
beads (GE Healthcare) and used for IP.
In vitro acetylation assays
HEK293T cells were transfected with green fluorescent
protein (GFP), ING3-HA, or AR-Myc and were lysed 24 h
post-transfection. GFP- or ING3-transfected cell lysates
were incubated with anti-HA, and AR-transfected cell ly-
sates were incubated with either anti-Myc or normal
rabbit IgG (Santa Cruz). For acetylation assays, IP samples
were washed once in histone acetyltransferase (HAT) buf-
fer (50 mM Tris-Cl pH 8.0, 10% glycerol, 0.1 mM EDTA,
10 mM butyric acid, 2 μM TSA). HA-IP samples were
mixed with protein A beads or control rabbit IgG IP. The
AR-IP sample was divided equally into two tubes and
mixed with HA-IP samples from either GFP- or ING3-
transfected cell lysates. Following addition of 1 mM acetyl
coenzyme A (Lithium salt, Sigma), all tubes were incu-
bated at 30 °C for 1 h with occasional shaking.
Luciferase reporter assays
We plated 5 × 104 HEK293T cells in 24-well plates and
transfected with the indicated plasmids, together with
AR3-tkk-LUC (a gift from Dr. Paul Rennie), pCMV-3myc-
AR, and a cytomegalovirus (CMV)-beta galactosidase
(PBL3-beta-gal) construct as a transfection control (a gift
from Dr. Shirin Bonni). Luciferase assays were performed
as described. Briefly, one day after transfection, cells were
washed with phosphate-buffered saline (PBS) and lysed
using reporter lysis buffer (Promega). 30 μl of each lysate
was transferred into 96-well plates, and luminescence was
detected using a Berthold luminometer. Beta-gal staining
was used as an internal control.
Chromatin immunoprecipitation (ChIP) and quantitative
PCR (qPCR)
The effects of ING3 knockdown on AR recruitment to the
FKBP5 ARE were determined by ChIP using 3 × 107 C4-2
cells transfected with siCtrl or siING3 for 48 h in media
supplemented with 5% CSS, +/– 10 nM MB. Cells were
crosslinked using 1% formaldehyde. Cells were lysed in
1 ml ChIP lysis buffer and sonicated for 8 × 12 s. After
centrifugation, the supernatants were immunoprecipitated
with rabbit anti-AR (N-20, Santa Cruz) or rabbit control
IgG overnight at 4 °C and incubated with Protein A Beads
(GE Healthcare) for 2 h at 4 °C. Immunoprecipitates were
washed with ChIP lysis buffer, with Tris-EDTA (TE)
buffer, and then eluted. The IP and input samples were
reverse crosslinked using NaCl at 65 °C overnight, and the
DNA was isolated. Binding of AR to the Androgen Re-
sponse Element (ARE) was tested using qPCR. The primer
sequences used were FKBP5 ARE6/7: Fwd 5'-
CCCCCCTATTTTAATCGGAGTAC-3' and Rev 5'-
TTTTGAAGAGCACAGAACACCCT-3', Non-specific
Fwd 5'-GGTCAGGTTTTGGTTGAGGA-3' and Rev 5'-
CAAGCACAGTGAGGGAGACA-3'. TRIzol and an
Omniscript ReverseTranscription kit (Qiagen) were used
for isolating total RNA and generating complementary
DNA (cDNA). Real-time PCR was performed using Max-
ima SYBR GreenMastermix (Fermentas) with an Applied
Biosystems 7900HT PCR system. The qPCR primer se-
quences are listed in Additional file 2: Table S1.
Tissue microarray (TMA) study and quantitative analysis
Sections (4-μm thick) were cut from TMA blocks and
deparaffinized in xylene, rinsed in ethanol, and rehydrated.
Heat-induced epitope retrieval was at 121 °C, pH 6 in Target
Retrieval Solution (Dako) for 3 min in a decloaking chamber
(Biocare Medical). Slides were stained using a Dako Auto-
stainer. Endogenous peroxidase activity was quenched with
peroxidase block (10 min, Dako) followed by a 15-min pro-
tein block (Signal Stain, Cell Signaling, Danvers, MA, USA).
Slides were washed with Tris-buffered saline with Tween
(TBST) and incubated at room temperature for 60 min with
Signal Stain protein block containing a 1:1500 dilution of
ING3 mouse mAb [24] and a 1:100 dilution of anti-pan-
cytokeratin rabbit polyclonal antibody (Dako). Secondary
reagents were incubated at room temperature for 60 min:
ready-to-use goat anti-mouse antibody conjugated to a
horseradish peroxidase-decorated dextran polymer back-
bone from the DAKO EnVision + system (Dako) and 1:200
dilution of Alexa-555 conjugated goat anti-rabbit antibody
(Invitrogen). Slides were washed with TBST and incubated
for 5 min with the Tyramide Signal Amplification (TSA)-
Plus Cy5 reagent (Perkin Elmer). After three washes in
TBST, slides were mounted with ProLong® Gold anti-fade
mounting medium containing DAPI and stored at 4 °C
overnight before scanning. For automated image acquisition
we used an Aperio Scanscope FL 8/10-bit monochrome
TDI line-image capture camera with filters specific for
DAPI, Cy3 (Alexa-555) to define the tumor cytosolic com-
partment based on cytokeratin, and Cy5 for ING3. Images
were analyzed using AQUAnalysis® version 2.3.4.1. Scores
were based on total percent area positive for ING3.
Immunofluorescence
Cells were grown on coverslips and fixed with 4% parafor-
maldehyde in PBS and permeabilized using 0.1% Triton
X-100 (Millipore) in PBS. Fixed cells were blocked using
5% BSA for 1 h. Ki67 antibody (Dako) or AR antibody (N-
20, Santa Cruz) were used at 1:200 in PBS for 2 h, washed
with PBS, and incubated with Alexa-488 goat anti-mouse
secondary antibody (1:1000 in PBS/5% bovine serum albu-
min (BSA)) for 1 h. Cells were then mounted on slides
and analyzed using an Axiovert 200 microscope.
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Cell survival and proliferation assay
LNCaP, PC3, and DU145 cells were transfected with siCtrl
or siING3 and 1 × 104 cells were seeded in 24-well plates.
The cells were washed twice and stained with 0.1% crystal
violet for 15 min at room temperature and washed.
Alamar Blue assays were performed to estimate cell prolif-
eration according to the manufacturer's protocol. Cell
proliferation was also monitored by seeding cells in 96-
well plates in parallel and counting cells at the indicated
times using a Celigo Cell Cytometer (Cyntellect).
Anchorage-independent soft agar assay
Agar (0.5%) was prepared in RPMI containing 10% FBS,
and 1 ml was poured into each well of 24-well plates to
form a bottom layer. 1 × 104 cells were then mixed with
RPMI-20% FBS containing 0.3% agarose and poured on
top of the bottom layer. Colonies were analyzed using an
inverted microscope 10 days after seeding. Colony
diameters were measured using ImageJ software, and the
colony volumes were calculated (4/3πr3).
Transwell migration assay
Transwell inserts (Corning) were placed in 24-well
plates, and 500 μl of RPMI-20% FBS was added to the
plate bottoms. We seeded 5 × 104 LNCaP cells on top of
the transwell inserts and supplemented with 250 μl of
RPMI + CSS or RPMI + 1 nM MB. The inserts were fixed
at the indicated time points with 4% paraformaldehyde
and methanol and stained with crystal violet. For quanti-
fication, six random fields were chosen, and the cells
were counted in a single-blinded fashion.
Wound healing assay
C4-2 cells stably infected with shING3 or shCtrl were
plated at 80% confluence in 6-well plates. Doxycycline
was added to induce the expression of shRNA, and the
cells were grown in RPMI supplemented with 10 nM
MB for the duration of the experiment. A 200-μl sterile
tip was used to wound the monolayers. At the indicated
time points, images were taken from the same fields
across the course of the experiment. The percentage of
healed wound was then calculated using the following
formula: 1-(surface area in one field)/(surface area of the
same field at day 0).
Statistics
All experiments were done in triplicate. Each patient's
tissue samples were punched in duplicate on TMA
slides. Graphpad Prism was used for graphs and statis-
tical analyses such as standard error calculations, confi-
dence intervals, Student's t tests and analysis of variance
(ANOVA) statistics. SPSS statistics software was used
for analyzing the TMA results including Kaplan-Meier
and Cox proportional hazard analyses.
Results
ING3 interacts with the AR
Since ING3 levels regulate PC cell proliferation and cor-
relate with prognosis in patients with ERG-negative PC,
we asked whether ING3 had any function in PC cells and
whether it interacts with the AR [25, 26, 28]. Correlation
analysis using The Cancer Genome Atlas (TCGA) pros-
tate adenocarcinoma cohort data (n = 498) indicated that
ING3 and AR mRNA levels were positively correlated
(Fig. 1a). To test whether this correlation extended to AR
function, we analyzed levels of ING3 and 25 common
androgen-regulated genes [29, 30]. Heatmaps of patient
samples (Fig. 1b) showed that ING3 correlates with overall
AR activity score as determined by the 25-gene signature
(Spearman rho = 0.21).
VCaP (AR-positive) metastatic PC cells also express
higher levels of ING3 compared to LNCaP and C4-2 cells
(Additional file 1: Figure S2A, B). To test if ING3 levels
correlated with AR activity, these cells were grown in
media supplemented with charcoal stripped serum (CSS)
for 48 h and treated with the androgen analog mibolerone
(MB), the anti-androgen bicalutamide (Bic), or ethanol as
a vehicle control. Both AR and ING3 levels increased in
response to MB and decreased in response to anti-
androgen in VCaP and LNCaP lines. In the C4-2 line, an
LNCaP subline of advanced PC with inducible levels of
AR and known resistance to anti-androgens, levels of
ING3 did not decrease in response to Bic [31, 32]
(Additional file 1: Figure S2C). The increase in ING3
protein levels was not a consequence of transcriptional
induction (Additional file 1: Figure S2D), but rather ING3
protein was stabilized in LNCaP cells treated with MB
where its estimated half-life increased from 1 h to 4 h
(Additional file 1: Figure S2E).
A number of co-activators, which interact with and
regulate the AR, have been described. To test if ING3
physically interacted with the AR, we immunoprecipitated
endogenous ING3 under non-denaturing conditions in
LNCaP cells. Probing of blots showed that the AR co-
precipitated ING3 in MB-stimulated, but not in unstimu-
lated cells (Fig. 1c). As shown in Additional file 1: Figure
S3A, HA-tagged ING3 could co-precipitate Myc-tagged
AR in the absence of MB stimulation when overexpressed,
but addition of MB increased ING3 levels and co-
precipitated more AR. Addition of ethidium bromide
(EtBr) to the IP buffer did not alter this interaction,
suggesting that the interaction was not dependent on
DNA (Additional file 1: Figure S3B) [33].
Nuclear translocation of the AR is a critical step in
activation, which involves a series of post-translational
modifications and protein interactions. We previously
found that ING3 localizes in both the nucleus and the
cytoplasm of cells in proliferating tissues [24]. To investi-
gate the subcellular localization of ING3 and the AR,
Nabbi et al. BMC Medicine  (2017) 15:103 Page 4 of 14
nuclear and cytoplasmic fractions of HEK293T cells
transfected with plasmids encoding AR and ING3 in the
absence of MB were prepared using the REAP fraction-
ation protocol [34]. ING3 co-immunoprecipitated the AR
in the cytoplasmic, but not the nuclear fraction, despite
the much higher levels of ING3 in the nucleus (Fig. 1d).
To examine the region of the AR required for interaction
with ING3, FLAG-tagged deletion constructs of AR were
co-transfected with ING3-HA into HEK293T cells. As
shown in Fig. 1e, a construct containing the DNA-binding
domain (DBD), but not one missing the DBD bound
ING3, suggesting that the DBD interacts directly with
ING3, or alters the structure of the AR to allow binding of
ING3 to the AR. The hinge (H) or ligand-binding domains
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(LBDs) of the AR did not alter this interaction (data not
shown).
ING3 regulates AR activity
To test if ING3 regulated the AR pathway, we overex-
pressed ING3 in LNCaP and C4-2 cells and analyzed the
expression of three androgen-regulated genes, PSA,
TMPRSS2, and FKBP5. As seen in Fig. 2a, ING3 potenti-
ated the effects of MB. Conversely, knockdown of ING3
in LNCaP cells (Fig. 2b) decreased responsiveness to MB,
affecting FKBP5 levels most prominently (Fig. 2c). ING3
also increased the levels of PSA in LNCaP cells, and ING3
knockdown in C4-2 cells decreased PSA protein levels
(Fig. 2d). Since the FKBP5 gene was regulated most
dynamically by ING3 and it functions in AR regulation
[35], we tested the effects of ING3 on AR binding to its
androgen response element (ARE) in C4-2 cells. MB
increased AR binding dramatically, and this increase was
blocked by ING3 knockdown (Fig. 2e).
A major function of ING3 is thought to be targeting the
TIP60 complex to the H3K4Me3 mark of active chroma-
tin to alter chromatin conformation [17]. We evaluated
the effects of ING3 on ARE-driven transcription using a
luciferase reporter system [36]. Knockdown of ING3
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homeodomain (PHD) deleted construct is shown. Cells were co-transfected with 1 μg AR3-tkk-LUC, 0.2 μg β-gal, 1 μg AR, and either empty vector,
full-length ING3 expression plasmid, or PHD deletion mutant in CSS medium for 48 h. Levels of ING3-HA expression were verified by western blotting
(left), and ARE-driven reporter expression is shown in response to full-length and PHD-deleted ING3 (right, t test *P < 0.05). j Co-precipitation using
HEK293T cells co-transfected with full-length AR, ING3, and an ING3 deletion mutant. HA beads were used to immunoprecipitate ING3 constructs. The
interacting AR and endogenous TIP60 were detected by western blotting with their respective antibodies
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reduced, but was not able to block the ability of MB to
induce luciferase expression driven by ARE (Fig. 2f), while
ING3 overexpression enhanced it (Fig. 2g). A time-course
experiment with 1 nM MB (Fig. 2h) showed that ING3
affects basal activity of the reporter, and this effect is amp-
lified proportionately over time in the presence of MB.
To further differentiate the chromatin effects of ING3
from its role in the cytoplasm, we performed the luciferase
reporter assay using either the wild type or an ING3 PHD
deletion mutant. The mutant was capable of stimulating
the ARE-driven reporter in the absence of MB to an
extent indistinguishable from the wild type (Fig. 2i). This
showed that the effects of ING3 on AR transactivation are
independent of the ING3 PHD and its chromatin-
targeting function. Indeed, the PHD deletion mutant co-
precipitated the AR and TIP60 (Fig. 2j), further confirm-
ing that the interaction was not dependent on the PHD.
ING3 promotes activation of the AR by TIP60
Since ING3 is an essential component of the TIP60
complex [20], and TIP60 is a known AR co-activator [10],
we asked whether ING3 contributed to TIP60-mediated
AR activation. Immunoprecipitates of endogenous TIP60
recovered AR in an MB-sensitive manner as previously
reported (Fig. 3a). When cells were co-transfected with
increasing amounts of ING3, increasing amounts of AR
protein were precipitated with HA-tagged TIP60 and vice
versa (Fig. 3b). ING3 increased association between AR and
TIP60 by about eightfold (Fig. 3b graph), while siING3
reduced association between AR and TIP60 by about three-
fold in C4-2 cells (Fig. 3c). An ARE luciferase assay showed
that siING3 largely abrogated the effects of increasing
TIP60 on AR transactivation in the absence or presence of
MB (Fig. 3d), consistent with ING3 facilitating interaction
between TIP60 and the AR. These results suggested that
ING3 promotes interaction between TIP60 and the AR.
ING3 promotes AR acetylation and nuclear localization
Since TIP60 acetylates AR and promotes its nuclear trans-
location [10, 37], we asked whether the ING3 component
of the TIP60 complex affects AR acetylation. Overexpres-
sion of ING3 increased AR acetylation, as estimated by
probing AR immunoprecipitates for acetyl lysine (Fig. 3e).
The in vitro acetylation assay shown in Fig. 3f, in which
immunoprecipitated ING3-HA was added to AR-IP
samples plus acetyl coenzyme A, confirmed that ING3
complexes acetylated the AR. In the complementary
experiment shown in Fig. 3g, knockdown of ING3 dra-
matically decreased the ability of TIP60 to acetylate AR.
Transfection with AR acetylation mutants K630R and
K632/33R [8] completely abrogated the effect of ING3
compared to transfection with wild-type AR (Fig. 3h).
Knockdown of ING3 also inhibited MB-induced trans-
location of the AR to the nucleus as seen in the
fractionation assay done using the REAP protocol [34]
shown in Fig. 3i. Overexpression of ING3 also increased
nuclear staining for AR in the absence of MB treatment
(Fig. 3j), corroborating previous data indicating a cyto-
plasmic function for ING3 in promoting TIP60-
mediated AR acetylation, leading to its nuclear
localization.
ING3 knockdown reduces PC cell growth
We next investigated the functional consequence of this
role of ING3 in PC cells by analyzing the growth of
LNCaP, PC3, and DU145 cells after ING3 knockdown.
Staining cells 10 days after plating showed that ING3
knockdown decreased proliferation of AR-positive and
AR-negative cell lines (Fig. 4a). This observation suggested
that ING3 can affect PC cell growth in both AR-
dependent and AR-independent manners. ING3 effects on
LNCaP (AR-positive) cell growth quantitated using
Alamar Blue assays and by counting cells 3 and 7 days
post-transfection of siING3 are shown in Fig. 4b, confirm-
ing the effects seen in Fig. 4a. Cell growth was also tested
using an automated live cell imaging system (IncyCyte
Zoom) over a course of 72 h after transfection with siCtrl
or siING3. As shown in Fig. 4c, ING3 knockdown also
reduced C4-2 cell growth using this independent assay.
The colony-forming capability of PC cells in soft agar was
also reproducibly reduced upon ING3 knockdown, with
average calculated volumes of siING3-transfected colonies
being less than half of those for cells transfected with con-
trol RNA (313 ± 50 vs. 153 ± 16 mm3, Fig. 4d), consistent
with cell counting and Alamar Blue assays. LNCaP cells
transfected with siING3 also showed significant reduction
in Ki67 staining compared to siCtrl, with the sample
shown in Fig. 4e further confirming that ING3 knock-
down reduced PC cell number by slowing their growth
rate. This observation was quantitated using LNCaP cells
infected with lentiviral shING3 in which 72% of cells in-
fected with control RFP lentivirus showed Ki67 staining
compared to 22% of cells infected with RFP + ING3 lenti-
virus (Additional file 1: Figure S4).
ING3 knockdown may reduce migration of PC cells
Transwell migration assays in the absence and presence of
MB (Additional file 1: Figure S5A, B) and wound healing
assays (Additional file 1: Figure S5C) showed that ING3
knockdown modestly reduced androgen-induced cell
migration in LNCaP and C4-2 cells. Consistent with a
previous report [25], ING3 also decreased the migration of
AR-negative PC3 and DU145 cells (Additional file 1:
Figure S5A, B), suggesting that an AR-independent mech-
anism exists by which ING3 can affect these cells. ING3
knockdown in LNCaP cells also reduced MB-induced filo-
podia formation as visualized by Alexa 568-conjugated
phalloidin staining (Additional file 1: Figure S5D, E),
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consistent with ING3 having an effect on migration, in
addition to effects on cell growth.
ING3 levels predict survival in patients with PC
Microarray slides containing 265 PC patient tissue sam-
ples were stained with a validated ING3 monoclonal anti-
body [24] and analyzed by automated quantitative
immunofluorescence (AQUA) using a blind experimental
protocol. Patient characteristics are shown in Additional
file 2: Table S2 with representative images of AR staining
in Additional file 1: Figure S6. As shown in Fig. 5a, cells
with high AR levels stained more intensely for ING3.
Examination of our PC cohort indicated a trend of higher
ING3 levels in samples with higher (7 or above) Gleason
scores compared with samples with Gleason scores below
7 (Fig. 5b), and similar results were seen using TCGA
prostate cohort data (not shown). To determine if ING3
had prognostic value in PC, we split the cohort into deriv-
ation and validation datasets [38]. Additional file 2: Table
S2 shows characteristics of the datasets validated by
Kaplan-Meier analysis using the Gleason score as the
known predictor (Additional file 1: Figure S7). ING3
AQUA scores were dichotomized using a 1.66 cutoff
based on the derivation dataset for testing in the valid-
ation dataset. Kaplan-Meier analysis based on AR status
showed that higher ING3 levels inversely correlated with
overall survival in patients with low AR levels (P =
0.00008) (Fig. 5c and Additional file 1: Figure S8). In
patients with low AR, ING3 predicted survival better than
Gleason score (compare Fig. 5c and d), but Gleason score
predicted survival better in patients with high AR levels
(data not shown). This suggests that under low AR levels
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Fig. 3 ING3 promotes AR acetylation and regulates its nuclear translocation. a TIP60 was immunoprecipitated from C4-2 lysates from cells grown +/– 10
nM MB for 24 h, and lysates were blotted for TIP60 and AR. b Cells were co-transfected with AR, TIP60, and increasing amounts of ING3 plasmid + 10 nM
MB for 24 h. AR or TIP60 was immunoprecipitated using α-AR or HA-affinity beads, respectively. The graph shows the average ratio of AR:HA-TIP60 in three
independent experiments (t test **P< 0.01). c C4-2 cells transfected with siCtrl or siING3 were treated for 24 h with MB, immunoprecipitated with α-TIP60,
and blotted with α-TIP60 or α-AR. The graph shows the average TIP60:AR ratio (t test *P< 0.05). d ARE reporter activity of cells co-transfected with 1 μg
AR3-tkk-LUC, 0.2 μg β-gal, 0.2 μg AR, 50 ng of TIP60, and 20 nM of either siCtrl or siING3 for 48 h +/– 1 nM MB for the final 24 h (ANOVA *P< 0.05). e
HEK293T cells were co-transfected with 1 μg of vector or AR construct +/– 0.2 μg ING3, and the AR acetylation was determined. The graph shows the
average ratio of Ac-AR:total AR (t test *P< 0.05). f, g HEK293T cells were co-transfected with AR-Myc, ING3-HA, or GFP (f) or with AR-Myc, siCtrl, or siING3
(g). AR was immunoprecipitated with α-myc. ING3 was immunoprecipitated with α-HA in GFP or ING3-transfected cells (f). TIP60 was immunoprecipitated
in siCtrl- or siING3-transfected cells (g). In vitro acetylation assays were performed using 1 mM of acetyl coenzyme A. h Cells were co-transfected with 1 μg
AR3-tkk-LUC, 0.2 μg β-gal, 0.2 μg of either vector or ING3, and 0.2 μg of either wild-type or mutant AR constructs for 48 h +/– 0.1 nM MB for 24 h. i LNCaP
cells were transfected with siCtrl or siING3 for 48 h. After 2 h of treatment with MB, nuclear and cytoplasmic fractions were blotted to detect AR. j LNCaP
cells were transfected with GFP or ING3-HA under androgen deprivation conditions and stained with anti-AR and anti-HA antibodies. The nuclear intensity
of AR staining for transfected cells and the adjacent untransfected cells was measured using ImageJ, and the relative ratio was graphed (t test *P< 0.05)
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overexpression of ING3 activates the AR pathway, while
in the context of higher AR expression, ING3 may not be
required for sufficient AR activity to drive cell growth.
ING3 levels were also useful in predicting the hazard
function using Cox proportional hazard analysis [39]. Fac-
tors such as AR levels, age, Gleason score, occurrence of
CRPC, and ERG were taken into consideration in the
multivariate analyses (Table 1 and Additional file 2: Tables
S3 and S4). The contribution of ING3 in predicting hazard
function was significant in both tested datasets with haz-
ard ratios of 3.309 and 2.571, respectively. Testing the re-
gression coefficients of Cox models on the two datasets
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Fig. 4 ING3 regulates prostate cancer cell proliferation. a LNCaP, DU145, and PC3 were seeded at equal density, transfected with siCtrl or siING3,
and 10 days later were fixed and stained with crystal violet. b LNCaP cells were grown in media supplemented with 5% CSS for the indicated
times, and cellular proliferation was assessed using Alamar Blue (left) or counted (right) at indicated times (t test (*P < 0.05 ***P < 0.001). c C4-2
cells were transfected with either siCtrl or siING3 under androgen deprivation conditions and seeded at equal density. Forty-eight h later cell pro-
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indicated that ING3 coefficients were not significantly dif-
ferent, implying that ING3 contributes similarly to the
outcome prediction and was independent of patient
dataset.
Perhaps more clinically relevant, when Cox regression
analyses +/–ING3 were performed and the likelihood ratios
(LRs) compared, ING3 significantly improved the Cox
model in prediction of the hazard function (ΔLR = 5.075, P
value = 0.024, ΔLR = 3.941, P value = 0.047 for derivation
and validation datasets, respectively). This set of results
suggests that ING3 could serve as a novel prognostic factor
in PC pathophysiology to help predict the aggressiveness of
the tumor, which should reduce the rate of overdiagnosis in
this patient population.
TIP60 EPC1
ING3
ARE
AR
AR
DHT
P23
FKBP5
HSP90
DHT
AR
P23
FKBP5
HSP90
DHT
AR
P23
FKBP5 HSP90
DHT
AR
Ac TIP60 EPC1
ING3
DHT
AR
Ac
AR
DHT
AR
Ac
Primary prostate cancer
Prostate cancer cells
Proliferation and migration
Normal luminal cells
Nucleus
FKBP5
e
b
0 50 100
0
20
40
60
80
100 GS=<7
GS>7
Overall survival time (Months)
O
ve
ra
ll
su
r v
iv
al
(%
)
p=0.0024
0 25 50 75 100
0
20
40
60
80
100
Low ING3
High ING3
p = 0.00008
Overall survival time (Months)
O
ve
ra
ll
su
rv
iv
al
(%
)
c d
AR LowAR High
ING3 ING3
PCK PCK
DAPI DAPI
MERGE MERGE
a
Low AR subgroup
GS
<7
GS
=7
GS
>7
0
1
2
3
5
10
15
**
IN
G
3
A
Q
U
A
sc
or
e
Lo
w
AR
Hi
gh
AR
0
1
2
3
4
5
5
10
15
20
25
30
***
IN
G
3
A
Q
U
A
sc
or
e
Low AR subgroup
Fig. 5 High ING3 levels correlate with poor prognosis in prostate cancer patients. a Representative images of patient samples and their ING3
staining (red), pan-cytokeratin (PCK) (green), and DAPI (blue) that were classified as having high or low AR levels. The graph shows ING3 AQUA
score in the patient subgroups based on their AR expression (Mann-Whitney test ***P < 0.001). b ING3 AQUA score in AR-low patient subgroup
with various Gleason scores (ANOVA **P < 0.01). c, d Kaplan-Meier overall survival curves for AR-low subgroup of patients based on ING3 protein
levels (c) or Gleason score (d) (log rank test). e Model of ING3 function in the AR pathway. ING3 serves as a scaffolding protein to coordinate
interaction between members of TIP60 KAT complex with the AR complex in the cytoplasm. This promotes AR acetylation by TIP60, leading to
nuclear translocation. Nuclear AR regulates gene expression promoting prostate cancer survival, proliferation, and migration. ING3 promotes AR
recruitment to the FKBP5 ARE (and a subset of other genes containing AREs) and increases FKBP5 mRNA levels. This generates a positive feedback
loop, making more FKBP5 available to bind AR, thereby stabilizing the complex, which promotes additional binding to ligand. Activation of this
pathway promotes proliferation and migration of AR-responsive prostate cancer cells
Table 1 Cox proportional hazard model for prostate
adenocarcinoma (PCA) cohort
Covariate Coefficient SE P value Hazard
ratio
95% CI
ING3 0.887 0.337 0.009 2.429 1.254–4.705
Age -0.662 0.387 0.725 0.993 0.956–1.032
CRPC 1.385 0.355 0.000096 3.995 1.992–8.012
Gleason score 1.803 0.503 0.0003 6.069 2.264–16.272
AR expression -0.206 0.334 0.537 0.814 0.423–1.566
ERG expression -0.007 0.019 0.087 0.516 0.242–1.1
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Discussion
The androgen receptor (AR) pathway is a major contribu-
tor to prostate cancer and, coupled with other oncogenic
signaling pathways, plays a key role in the initiation and
progression of this disease [40, 41]. In this study, we have
identified ING3 as a novel AR co-activator in PC. Altering
ING3 levels in PC cells showed that it positively regulates
AR, enhancing effects of androgens on the expression of
AR-regulated genes and an ARE-driven reporter. ING3
exerts this effect by promoting AR-TIP60 interaction,
thereby increasing the acetylation of AR, its translocation
to the nucleus, and activation as a transcription factor. This
does not require the ING3 PHD region that interacts spe-
cifically with the H3K4Me3 [19, 20, 42], identifying a novel
chromatin-independent role of ING3. Moreover, knock-
down of ING3 inhibits PC cell growth, indicating that
ING3 plays an oncogenic role in prostate cancer. In con-
trast to previous studies in other tumor types where ING3
was reported to function as a tumor suppressor, we find
that ING3 levels are higher in aggressive PCs, and that a
high level of ING3 is a prognostic factor predicting poorer
survival in patients with low AR levels. A model for how
our data suggest that ING3 functions to activate the AR
signaling pathway in PC biology is shown in Fig. 5e.
A carboxyl-terminal deletion mutant of ING3 lacking
the PHD (Fig. 2i) interacted with and efficiently activated
the AR. This function is likely distinct from epigenetic
properties of ING3 since this form of ING3 is incapable of
targeting the TIP60 complex to the H3K4Me3 mark. Simi-
lar PHD-independent effects for ING family proteins were
seen for ING2 during C2C12 myoblast differentiation [43]
and ING4-induced apoptosis in prostate epithelium [44].
These data indicate two distinct functions for ING3, one
in coordinating a cytoplasmic complex to enhance AR
acetylation efficiency and another to target the TIP60
complex to chromatin via recognition of H3K4Me3. Al-
tered localization of ING1 in brain cancers [45] and its
shuttling from the cytoplasm to nucleus by interaction
with 14-3-3 proteins [46] are consistent with ING proteins
functioning in multiple cell compartments.
Recently, the PHD of ING3 was reported to be essential
for DNA damage-induced apoptosis in MCF-7 cells where
interaction between the ING3 PHD and the H3K4Me3
mark was reported to be in the submicromolar range [47].
In contrast to this role, we have identified a chromatin-
independent function for both full-length ING3 and a
shorter isoform lacking the C-terminal domain. These
differential functions of ING3 isoforms are not well defined
and require further investigation. Consistent with our ob-
servation that ING3 interacts with and targets the TIP60
KAT complex to activate the AR by acetylation, a recent
study reported that ING1, a stoichiometric member of the
Sin3A KDAC complex [17] that directs deacetylation activ-
ity, functions as an AR co-repressor [48]. These and other
studies, therefore, support the idea that the ING proteins
can function to target acetylation and deacetylation activ-
ities to the H3K4Me3 mark in chromatin, as well as serve
as scaffolding proteins to promote the acetylation or deace-
tylation of target proteins in the cytoplasm that have major
impact on biological processes such as the AR pathway.
AR acetylation is known to be an essential step in AR acti-
vation, and increased activity of KATs such as p300 and
TIP60 is involved in progression of PC [8–10]. This post-
translational modification occurs in the hinge region of AR,
leading to nuclear localization signal (NLS) unmasking and
nuclear translocation. ING3 promoted TIP60-AR associ-
ation in the cytoplasm, inducing AR acetylation, nuclear
translocation, and activation of target genes, including
FKBP5, an immunophilin that regulates the AR, NF-kB, and
the glucocorticoid receptor [49]. FKBP5, induced by AR via
several AREs, modulates the AR pathway through forming a
positive feedback loop [35, 50, 51] as noted in Fig. 5e. While
we observed ING3 effects on AR binding to the FKBP5-
ARE, the role of other pathways in regulation of this and
other AR-sensitive genes cannot be excluded. The differen-
tial effects of ING3 on FKBP5 as well as other selected
androgen-regulated genes in this study underline the
complex nature of the regulation of these genes. Indeed,
according to the ENCODE data portal, there are several
other transcription factors that can occupy the promoters of
PSA, TMPRSS2, and FKBP5, the list of which interestingly
includes (but is not limited to) other members of the nuclear
receptor family. It is therefore likely that the overall effect of
ING3 on selected genes can be due to its differential regula-
tion of other transcription factors, independent of its AR-
activating function. The interaction of ING3 with the DNA-
binding domain of the AR, which is the most conserved
domain among nuclear receptors, further suggests other
functions beyond the AR; these remain unclear at this point
and require additional investigation. This interaction can
also be of clinical relevance in prostate cancer, as AR splice
variants that lack an intact DNA-binding domain are de-
scribed as one of the mechanisms promoting CRPC [52].
When PC cells were grown in an androgen-depleted
medium that mimics clinical androgen deprivation therapy
(ADT) conditions, ING3 knockdown significantly reduced
cell growth. Consistent with this observation, an independent
RNA interference-based screen identified ING3 as a positive
regulator of proliferation and survival in androgen-deprived
VCaP cells [28]. This is of clinical significance, as resistance
to ADT is one of the important challenges in PC manage-
ment. However, ING3 knockdown also reduced the growth
and migration of AR-negative prostate cancer cells, DU145
and PC3, indicating its role in AR-independent pathways.
This is likely considering the fact that ING3 and its associ-
ated KAT complex are epigenetic regulators with diverse cel-
lular functions [53]. While we report the novel role of ING3
in AR pathway activation, the effects on global gene
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regulation and chromatin remodeling, as expected from this
class of proteins, should not be overlooked. Indeed, our pre-
liminary observations suggest that ING3 can affect cell cycle
pathways through its chromatin binding properties.
In contrast to previous studies in melanoma and hepato-
cellular carcinoma reporting reduced ING3 levels in aggres-
sive cancers [54], our analyses of primary prostate tumors
showed that high levels of ING3 predict poorer outcome in
patients with low AR levels. A similar trend was observed
when analyzing recurrence rate using TCGA data stratified
based on AR levels (data not shown). This indicates that
higher ING3 levels can compensate for low AR levels by ac-
tivating AR, promoting PC growth. In the context of AR
hyperactivation, ING3 may not be required in the process
and may primarily function through gene regulation, for ex-
ample, by reducing apoptosis upon RSK-mediated suppres-
sion [55]. In addition to the effects of androgens and AR
antagonists, epithelial-mesenchymal transition (EMT) and
invasion of PC cells were recently reported to be dependent
on the levels of AR protein, with low levels of AR promot-
ing androgen-induced EMT [56]. This is in line with our
findings that ING3 modulated cell migration and that
higher ING3 levels correlated with poorer outcome in the
subset of patients having tumors with low levels of AR. We
recently found that high levels of ING3 also correlate with
poorer survival in ERG-negative PC [25]. Although the
interplay between ERG and AR remains unclear, several
studies have suggested that the ERG fusion protein inhibits
AR expression and activity at several loci [57], supporting
the idea that ING3 can potentiate the activity of the AR
pathway, particularly when AR inhibitory factors such as
ERG are absent. Together, these data identify ING3 as a
proto-oncogene in PC by regulating the AR pathway
through acetylation, and identify it as a novel prognostic
biomarker for primary prostate cancer.
Conclusions
In this study we show that ING3 regulates the AR pathway
in prostate cancer by virtue of acting as a scaffolding compo-
nent of the TIP60 complex, promoting AR acetylation, its
nuclear translocation, and the activation of androgen-
responsive genes. This study has also validated ING3 as a
novel prognostic biomarker that can dramatically improve
prediction of overall survival in prostate cancer, particularly
in cases with low levels of AR.
Additional files
Additional file 1: Figure S1. The four panels show representative
images of a line of C4-2 cells stably infected with inducible lentiviral
shCtrl or shING3, with or without Dox. The western blots show the
efficiency of ING3 knockdown in the presence or absence of Dox.
Figure S2. (A) Lysates from three AR-positive prostate cancer cell lines
were subject to western blotting with antibodies against ING3, GAPDH,
and actin. (B) mRNA levels of ING3 were normalized to actin in three
prostate cancer cell lines. (C) LNCaP, C4-2, and VCaP cells were grown in
media with charcoal stripped serum (CSS) for 48 h and treated with miboler-
one (MB) or bicalutamide (Bic). Protein levels of ING3 and AR were visualized
by western blotting with actin used as a loading control. (D) qRT-PCR study
of ING3 in LNCaP cells after treatment with increasing concentrations of MB.
The left graph shows mRNA levels of ING3 in response to MB. The right
graph shows mRNA levels of seven androgen-regulated genes in response
to MB. (E) A cycloheximide experiment using LNCaP cells grown in the
presence or absence of MB to estimate ING3 half-life. Figure S3. (A)
HEK293T cells were co-transfected with 1 μg of Myc-tagged AR and 1 μg of
either empty vector or HA-tagged ING3 +/– 10 nM MB. ING3 was pulled
down with HA-affinity beads, and precipitates were blotted with α-AR and
α-HA. (B) To determine the effects of DNA on the interaction, co-
immunoprecipitations were repeated with addition of ethidium bromide
(EtBr). ING3 was precipitated using HA-affinity beads. Figure S4. LNCaP cells
were infected with shCtrl or shING3 lentiviral particles for 72h under andro-
gen deprived conditions and stained with anti-Ki67. Arrows indicate infected
(RFP-positive) cells with associated Ki67 staining. RFP-positive and Ki67-
positive cells were counted and percentages are shown in the table. Figure
S5. ING3 affects PC migration. (A) LNCaP, PC3, and DU145 cells were trans-
fected with either siCtrl or siING3 and, in case of LNCaP, treated with 1 nM
MB for the times indicated. Transwell migration assays were performed at
the indicated time points. Representative images are shown. (B) Images
were taken from six random fields for each condition and counted manually
on a computer using a blind experimental protocol (t test * < 0.05,
** < 0.01). (C) Wounds were made in monolayers of C4-2 cells stably
expressing either shCtrl or shING3 in the presence of 10 nM MB and Dox to
induce shRNA expression. Wounds were then allowed to heal during a
course of 4 days. Images were taken from the same fields for each
condition. Percentage of healed wound was then calculated based on pixels
observed in each condition. (D) LNCaP cells were transfected with siCtrl or
siING3 and treated with 1 nM MB for 72 h, then fixed and stained with Texas
Red-conjugated phalloidin. Arrows highlight actin projections along cell axes
consistent with filopodia formation. (E) The numbers of actin projections per
cell were counted in a blind experimental protocol from a total of 50 cells,
and the mean number of filopodia/cell was plotted (t test *** < 0.001).
Figure S6. Representative images of prostate cancer samples showing low
and high expression of AR as determined by immunohistochemistry.
Samples are from the prostate cancer patient cohort used in this study.
Figure S7. Kaplan-Meier survival curves using Gleason score as a known
prognostic marker in the derivation and validation datasets. Figure S8.
Kaplan-Meier survival curves in our prostate cancer patient cohort with low
levels of AR, in the derivation and validation datasets. (PPT 4506 kb)
Additional file 2: Table S1. List of primers for qPCR experiments. Table
S2. Patient characteristics in prostate cancer cohort and the derived datasets.
Table S3. Cox proportional hazard model for derivation dataset. Table S4.
Cox proportional hazard model for validation dataset. (DOCX 115 kb)
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